OM
AGRX

Opaleye Management’s Agile Therapeutics AGRX Stock Holding History

Opaleye Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-8
Closed -$85K – 49
2016
Q4 		$85K Buy
+8
New +$112K 0.05% 40
2016
Q1 		– Sell
-150
Closed -$2.93M – 61
2015
Q4 		$2.93M Sell
150
-43
-22% -$680K 1.22% 34
2015
Q3 		$2.6M Buy
193
+165
+589% +$2.93M 1.28% 33
2015
Q2 		$472K Buy
+28
New +$597K 0.19% 43

Other funds holding AGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Opaleye Management's AGRX Position: Q1 2017 in Review

Opaleye Management sold out of Agile Therapeutics (AGRX) in Q1 2017, closing a stake of 8 shares — an estimated $85K sold.

Opaleye Management first reported a position in AGRX in Q2 2015 and held it in 4 quarters. The position peaked at $2.93M in Q4 2015. 48 funds tracked by Wall St. Rank hold AGRX as of Q1 2017.

  • Opaleye Management reported no remaining Agile Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Opaleye Management sold 8 Agile Therapeutics shares in Q1 2017, an estimated $85K.
  • Opaleye Management first reported a position in Agile Therapeutics in Q2 2015 and held it in 4 quarters.
  • Opaleye Management's Agile Therapeutics position peaked at $2.93M in Q4 2015.
  • 48 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2017.

Based on Opaleye Management's 13F filing for Q1 2017, filed 15 May 2017.